Publications Repository - Helmholtz-Zentrum Dresden-Rossendorf

2 Publications
Radium-doped BaSO4 Nanoparticles for Future Targeted Alpha Therapy
Reissig, F.; Pietzsch, H.-J.; Steinbach, J.; Mamat, C.ORC
Targeted alpha therapy (TAT) is continually focused and discussed in radiopharmaceutical research [1]. By the combination of an alpha emitting radionuclide with a biological targeting unit, tumor cells can be affected very efficiently by inducing a high number of double strand breaks to the DNA. 223Ra and 224Ra are two alpha-emitting radionuclides with suitable half-lives for TAT. 223Ra in form of [223Ra]RaCl2 (Xofigo®) is the only EMA- and FDA-approved alpha-emitting radiopharmaceutical as well as the prime example for the working principle of TAT. Based on its calcimimetic behavior, radium is built into the bone structure. To exploit the therapeutic potential of alpha emitters like 223Ra and 224Ra, novel targeting strategies and carrier systems have to be developed. Therefore, it is worth to examine alternative carriers like nanoparticles, using the principle of co-precipitation of Ra/BaSO4. By the combination of a therapeutic alpha-emitting radionuclide like 223Ra on the one hand and the diagnostically applicable barium radioisotope 131Ba on the other hand with nearly identical physical half-lives it is also possible pursue theragnostic approaches. Thus, our research aims at developing a simple method for the synthesis of small radiolabeled Ra/BaSO4 nanoparticles and testing further surface functionalization regarding the ability of constructing biological targeting moieties.
Keywords: Radium-224, Barium-131, Nanoparticle
  • Poster
    23rd International Symposium on Radiopharmaceutical Sciences (ISRS 2019), 26.-31.05.2019, Peking, China
  • Open Access LogoAbstract in refereed journal
    Journal of Labelled Compounds and Radiopharmaceuticals 62(2019), S265

Publ.-Id: 29040 - Permalink